High-risk nonmuscle invasive bladder cancer

The majority of newly diagnosed bladder cancers (75% to 80%) are classified as nonmuscle invasive bladder cancer (NMIBC). Treatment for NMIBC often includes intravesical therapies. In particular, for patients with high-risk NMIBC, including those with carcinoma in situ, high-grade T1, or large-volume or recurrent Ta tumors, guidelines recommend treatment after transurethral resection with intravesical bacillus Calmette-Guerin (BCG). Although […]

High-risk nonmuscle invasive bladder cancer Read More »